Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).

被引：7
|
作者：
Dang, Nam H.
Ogura, Michinori
Castaigne, Sylvie
Fayad, Luis
Jerkeman, Mats
Radford, John A.
Pezzutto, Antonio
Bondarenko, Igor
Stewart, Douglas Allan
Shnaidman, Michael
Sullivan, Sharon
Vandendries, Erik
Tobinai, Kensei
Ramchandren, Rod
Hamlin, Paul A.
Gine, Eva
Ando, Kiyoshi
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan
[3] Hosp Versailles, Versailles, France
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[5] Skane Univ Hosp, Lund, Sweden
[6] Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[7] Charite, Dept Hematol Oncol & Tumor Immunol, D-13353 Berlin, Germany
[8] Municipal Clin Hosp 4, State Med Acad, Dnepropetrovsk, Ukraine
[9] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[10] Pfizer Inc, New York, NY USA
[11] Pfizer, Cambridge, MA USA
[12] Pfizer Inc, Cambridge, MA USA
[13] Natl Canc Ctr, Tokyo, Japan
[14] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[16] Hosp Quiron Barcelona, Inst Oncol Baselga, Unidad Hematol, Barcelona, Spain
[17] Tokai Univ, Sch Med, Univ Hosp, Hiratsuka, Kanagawa 25912, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8529
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Hatake, Kiyohiko
    Ogura, Michinori
    Ando, Kiyoshi
    Tokushige, Kota
    Ono, Chiho
    Vandendries, Erik R.
    Tobinai, Kensei
    BLOOD, 2010, 116 (21) : 1183 - 1183
  • [23] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [24] AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
    Leonard, John
    Gribben, John G.
    Trneny, Marek
    Scheinberg, Phillip
    Kilavu, Nurgul
    Patturajan, Moore
    Fustier, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
    Changhee Park
    Ho Sup Lee
    Ka-Won Kang
    Won-Sik Lee
    Young Rok Do
    Jae-Yong Kwak
    Ho-Jin Shin
    Sung-Yong Kim
    Jun Ho Yi
    Sung-Nam Lim
    Jeong-Ok Lee
    Deok-Hwan Yang
    Hun Jang
    Byoungsan Choi
    Jiwoo Lim
    Choong Hyun Sun
    Ja Min Byun
    Sung-Soo Yoon
    Youngil Koh
    Nature Communications, 15
  • [26] a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Maddocks, Kami J.
    Cohen, Jonathon B.
    Huang, Ying
    Christian, Beth A.
    Benson, Don M.
    Jones, Jeffrey
    Flowers, Christopher
    Heffner, Leonard T.
    Jenkins, Cynthia
    Sexton, Jennfer
    Neal, Alison
    Kives, Melissa
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [27] Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
    Park, Changhee
    Lee, Ho Sup
    Kang, Ka-Won
    Lee, Won-Sik
    Do, Young Rok
    Kwak, Jae-Yong
    Shin, Ho-Jin
    Kim, Sung-Yong
    Yi, Jun Ho
    Lim, Sung-Nam
    Lee, Jeong-Ok
    Yang, Deok-Hwan
    Jang, Hun
    Choi, Byoungsan
    Lim, Jiwoo
    Sun, Choong Hyun
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [28] Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye J.
    Lee, Seung S.
    Kim, Kyeong M.
    Choi, Tae H.
    Cheon, Gi J.
    Kim, Won S.
    Suh, Cheolwon
    Yang, Sung H.
    Lim, Sang M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 136 - +
  • [29] Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+B-cell Non-Hodgkin Lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Davies, Andrew
    Crump, Michael
    Ananthakrishnan, Revathi
    Ishibashi, Taro
    Paccagnella, M. Luisa
    Boni, Joseph
    Vandendries, Erik
    MacDonald, David
    CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4807 - 4816
  • [30] Multicenter phase II study of oral fludarabine phosphate (FAMP) in relapsed indolent B-cell non-Hodgkin lymphoma (B-NHL)
    Morishima, Y
    Ogura, M
    Tobinai, K
    Minami, H
    Hayashi, M
    Hotta, T
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 155
12345